KR20140045433A - 아밀린 펩티드 및 그의 유도체 및 용도 - Google Patents

아밀린 펩티드 및 그의 유도체 및 용도 Download PDF

Info

Publication number
KR20140045433A
KR20140045433A KR1020137033991A KR20137033991A KR20140045433A KR 20140045433 A KR20140045433 A KR 20140045433A KR 1020137033991 A KR1020137033991 A KR 1020137033991A KR 20137033991 A KR20137033991 A KR 20137033991A KR 20140045433 A KR20140045433 A KR 20140045433A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
lys
polypeptide
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137033991A
Other languages
English (en)
Korean (ko)
Inventor
쳉자오 순
마노지 피. 사만트
스웨타 네라베틀라
Original Assignee
아밀린 파마슈티칼스, 엘엘씨.
아스트라제네카 파마수티컬스 엘피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아밀린 파마슈티칼스, 엘엘씨., 아스트라제네카 파마수티컬스 엘피 filed Critical 아밀린 파마슈티칼스, 엘엘씨.
Publication of KR20140045433A publication Critical patent/KR20140045433A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020137033991A 2011-05-25 2012-05-24 아밀린 펩티드 및 그의 유도체 및 용도 Withdrawn KR20140045433A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161489781P 2011-05-25 2011-05-25
US61/489,781 2011-05-25
PCT/US2012/039431 WO2012162542A1 (en) 2011-05-25 2012-05-24 Amylin peptides and derivatives and uses thereof

Publications (1)

Publication Number Publication Date
KR20140045433A true KR20140045433A (ko) 2014-04-16

Family

ID=47217749

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137033991A Withdrawn KR20140045433A (ko) 2011-05-25 2012-05-24 아밀린 펩티드 및 그의 유도체 및 용도

Country Status (17)

Country Link
US (1) US20140221287A1 (https=)
EP (1) EP2714067A1 (https=)
JP (1) JP2014516049A (https=)
KR (1) KR20140045433A (https=)
CN (1) CN103826655A (https=)
BR (1) BR112013030067A2 (https=)
CA (1) CA2837104A1 (https=)
CL (1) CL2013003377A1 (https=)
CO (1) CO6821894A2 (https=)
EA (1) EA201391763A1 (https=)
IL (1) IL229449A0 (https=)
MX (1) MX2013013802A (https=)
PH (1) PH12013502385A1 (https=)
SG (1) SG194998A1 (https=)
TN (1) TN2013000491A1 (https=)
WO (1) WO2012162542A1 (https=)
ZA (1) ZA201309679B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
WO2016034604A1 (en) * 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
CN104327162A (zh) * 2014-09-28 2015-02-04 苏州普罗达生物科技有限公司 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
WO2018144671A1 (en) * 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
CA3097812A1 (en) * 2018-04-25 2019-10-31 Janssen Pharmaceutica Nv Thioether cyclic peptide amylin receptor modulators
WO2020088645A1 (en) 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
TWI815327B (zh) 2021-03-03 2023-09-11 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
CA3257452A1 (en) 2022-05-27 2025-04-15 Hangzhou Sciwind Biosciences Co., Ltd. ANALOGUE OF HUMAN AMYLIN, DERIVATIVES AND USES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE471340T1 (de) * 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
MX2010005317A (es) * 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.

Also Published As

Publication number Publication date
CN103826655A (zh) 2014-05-28
CO6821894A2 (es) 2013-12-31
IL229449A0 (en) 2014-01-30
SG194998A1 (en) 2013-12-30
MX2013013802A (es) 2014-04-25
CL2013003377A1 (es) 2014-07-04
EA201391763A1 (ru) 2014-04-30
BR112013030067A2 (pt) 2016-11-29
ZA201309679B (en) 2016-10-26
NZ618526A (en) 2015-09-25
CA2837104A1 (en) 2012-11-29
JP2014516049A (ja) 2014-07-07
PH12013502385A1 (en) 2014-01-13
US20140221287A1 (en) 2014-08-07
TN2013000491A1 (en) 2015-03-30
EP2714067A1 (en) 2014-04-09
WO2012162542A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
KR20140045433A (ko) 아밀린 펩티드 및 그의 유도체 및 용도
US20140221282A1 (en) Long duration dual hormone conjugates
US20140249076A1 (en) Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
TWI700291B (zh) 升糖素及glp-1共激動劑化合物
KR102092025B1 (ko) 페길화된 옥신토모둘린 변이체
US9879063B2 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
US20150111246A1 (en) Site-specific enzymatic modification of exendins and analogs thereof
US9217022B2 (en) GLP-1 receptor agonist compounds having stabilized regions
JP2017141232A (ja) 作用持続時間が増した改変ポリペプチド
US9018160B2 (en) Peptide tyrosine tyrosine analogues
JP2022191398A (ja) アシル化ｇｌｐ－１誘導体
JP2017509698A (ja) プレプログルカゴンから誘導可能なペプチドホルモン類似体
CN101189335B (zh) 瘦素拮抗剂
US20110118183A1 (en) N-glycosylated human growth hormone with prolonged circulatory half-life
AU2012258714A1 (en) Amylin peptides and derivatives and uses thereof
NZ618526B2 (en) Amylin peptides and derivatives and uses thereof
HK1198008A (en) Amylin peptides and derivatives and uses thereof
CN115819551A (zh) 一种定点改造的一类glp-1/胰高血糖素/胃泌素受体三重激动剂及其应用
CN116514952B (zh) 一类glp-1类似物及其应用
TW202611064A (zh) Gipr和glp-1r共激動多肽及其用途
CN119488582A (zh) 一种glp-1和pyy孪药及其制备方法和应用
CN117186189A (zh) 一种兼具降糖和减重作用的glp-1/cck-1受体双重激动多肽及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid